利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

29 条记录 (耗时 0.035 秒)

    SELECTIVE TARGETING OF TUMOR VASCULATURE USING RADIOLABELLED ANTIBODY MOLECULES
    2.
    发明申请
    SELECTIVE TARGETING OF TUMOR VASCULATURE USING RADIOLABELLED ANTIBODY MOLECULES 审中-公开
    使用放射性抗体分子的肿瘤血管的选择性靶向

    公开(公告)号：US20090214423A1

    公开(公告)日：2009-08-27

    申请号：US12350346

    申请日：2009-01-08

    申请人： Laura Borsi ,  Enrica Balza ,  Barbara Carnemolla ,  Patrizia Castellani ,  Luciano Zardi ,  Matthias Friebe ,  Christoph-Stephan Hilger

    发明人： Laura Borsi ,  Enrica Balza ,  Barbara Carnemolla ,  Patrizia Castellani ,  Luciano Zardi ,  Matthias Friebe ,  Christoph-Stephan Hilger

    IPC分类号： A61K51/10 ,  A61P35/00

    CPC分类号： A61K51/1045

    摘要： A specific binding member that binds human ED-B, wherein the specific binding member is labelled with an isotope selected from the group consisting of 76Br, 77Br, 123I, 124I, 131I and 211At and comprises an antigen-binding site that comprises an antibody VH domain and an antibody VL domain, wherein the antibody VH domain is selected from the group consisting of the L19 VH domain, and a VH domain comprising a VH CDR1, a VH CDR2 and a VH CDR3, wherein the VH CDR3 is the L19 VH CDR3 of SEQ ID NO. 3, the VH CDR1 is optionally L19 VH CDR1 of SEQ ID NO. 1, and the VH CDR2 is optionally L19 VH CDR2 of SEQ ID NO. 2; and wherein the antibody VL domain is optionally selected from the group consisting of the L19 VL domain, and a VL domain comprising a VL CDR1, a VL CDR2 and a VL CDR3, wherein the VL CDR3 is the L19 VL CDR3 of SEQ ID NO. 6, the VL CDR1 is optionally L19 VL CDR1 of SEQ ID NO. 4, and the VL CDR2 is optionally L19 VL CDR2 of SEQ ID NO. 5; the L19 VH domain and L19 VL domain sequences being disclosed in Pini et al. (1998) J. Biol. Chem. 273: 21769-21776; wherein the specific binding member comprises a mini-immunoglobulin comprising said antibody VH domain and antibody VL domain fused to εS2-CH4 and dimerized or comprises a whole IgG1 antibody molecule; also methods and uses employing such a specific binding member.

    摘要翻译： 结合人ED-B的特异性结合成员，其中所述特异性结合成员用选自76Br，77Br，123I，124I，131I和211At的同位素标记，并且包含抗原结合位点，其包含抗体VH 结构域和抗体VL结构域，其中抗体VH结构域选自L19VV结构域和包含VH CDR1，VH CDR2和VH CDR3的VH结构域，其中VH CDR3是L19 VH CDR3 的SEQ ID NO： 3，VH CDR1任选是SEQ ID NO：1的L19VV CDR1。 1，VH CDR2任选是SEQ ID NO：1的L19VH CDR2。 2; 并且其中抗体VL结构域任选地选自L19VL结构域和包含VL CDR1，VL CDR2和VL CDR3的VL结构域，其中VL CDR3是SEQ ID NO：1的L19VL CDR3。 如图6所示，VL CDR1任选是SEQ ID NO：1的L19VL CDR1。 4，VL CDR2任选是SEQ ID NO：1的L19VL CDR2。 5; Pini等人公开了L19VV结构域和L19VL结构域序列 （1998）J.Biol.Chem。 Chem。 273：21769-21776; 其中所述特异性结合成员包含包含所述抗体VH结构域的微型免疫球蛋白和与ε2-CH4融合并且二聚化或包含整个IgG1抗体分子的抗体VL结构域; 也是采用这种特异性结合成员的方法和用途。

    Selective targeting of tumor vasculature using radiolabelled antibody molecules
    3.
    发明申请
    Selective targeting of tumor vasculature using radiolabelled antibody molecules 审中-公开
    使用放射性标记的抗体分子选择性靶向肿瘤脉管系统

    公开(公告)号：US20050074401A1

    公开(公告)日：2005-04-07

    申请号：US10937882

    申请日：2004-09-10

    申请人： Laura Borsi ,  Enrica Balza ,  Barbara Carnemolla ,  Patrizia Castellani ,  Luciano Zardi ,  Matthias Friebe ,  Christoph-Stephan Hilger

    发明人： Laura Borsi ,  Enrica Balza ,  Barbara Carnemolla ,  Patrizia Castellani ,  Luciano Zardi ,  Matthias Friebe ,  Christoph-Stephan Hilger

    IPC分类号： A61K51/00 ,  A61K51/10 ,  A61P35/00 ,  C07K16/46

    CPC分类号： A61K51/1045

    摘要： A specific binding member that binds human ED-B, wherein the specific binding member is labelled with an isotope selected from the group consisting of 76Br, 77Br, 123I, 124I, 131I and 211At and comprises an antigen-binding site that comprises an antibody VH domain and an antibody VL domain, wherein the antibody VH domain is selected from the group consisting of the L19 VH domain, and a VH domain comprising a VH CDR1, a VH CDR2 and a VH CDR3, wherein the VH CDR3 is the L19 VH CDR3 of SEQ ID NO. 3, the VH CDR1 is optionally L19 VH CDR1 of SEQ ID NO. 1, and the VH CDR2 is optionally L19 VH CDR2 of SEQ ID NO. 2; and wherein the antibody VL domain is optionally selected from the group consisting of the L19 VL domain, and a VL domain comprising a VL CDR1, a VL CDR2 and a VL CDR3, wherein the VL CDR3 is the L19 VL CDR3 of SEQ ID NO. 6, the VL CDR1 is optionally L19 VL CDR1 of SEQ ID NO. 4, and the VL CDR2 is optionally L19 VL CDR2 of SEQ ID NO. 5; the L19 VH domain and L19 VL domain sequences being disclosed in Pini et al. (1998) J. Biol. Chem. 273: 21769-21776; wherein the specific binding member comprises a mini-immunoglobulin comprising said antibody VH domain and antibody VL domain fused to εS2-CH4 and dimerized or comprises a whole IgG1 antibody molecule; also methods and uses employing such a specific binding member.

    摘要翻译： 结合人ED-B的特异性结合成员，其中特异性结合成员用选自76 Br，77 Br，123 I，124 I，131 I的同位素标记。 I和211包含抗体结合位点，其包含抗体VH结构域和抗体VL结构域，其中抗体VH结构域选自L19VV结构域和包含VH CDR1的VH结构域 ，VH CDR2和VH CDR3，其中VH CDR3是SEQ ID NO.1的L19VV CDR3。 3，VH CDR1任选是SEQ ID NO：1的L19VV CDR1。 1，VH CDR2任选是SEQ ID NO：1的L19VH CDR2。 2; 并且其中抗体VL结构域任选地选自L19VL结构域和包含VL CDR1，VL CDR2和VL CDR3的VL结构域，其中VL CDR3是SEQ ID NO：1的L19VL CDR3。 如图6所示，VL CDR1任选是SEQ ID NO：1的L19VL CDR1。 4，VL CDR2任选是SEQ ID NO：1的L19VL CDR2。 5; Pini等人公开了L19VV结构域和L19VL结构域序列 （1998）J.Biol.Chem。 Chem。 273：21769-21776; 其中所述特异性结合成员包含包含所述抗体VH结构域的微型免疫球蛋白和与ε2-CH4融合并且二聚化或包含整个IgG1抗体分子的抗体VL结构域; 也是采用这种特异性结合成员的方法和用途。

    SMALL TECHNETIUM-99M AND RHENIUM LABELED AGENTS AND METHODS FOR IMAGING TUMORS
    10.
    发明申请
    SMALL TECHNETIUM-99M AND RHENIUM LABELED AGENTS AND METHODS FOR IMAGING TUMORS 审中-公开
    小技术-99M和氙标签代理和成像肿瘤的方法

    公开(公告)号：US20080226550A1

    公开(公告)日：2008-09-18

    申请号：US12017328

    申请日：2008-01-21

    申请人： Ashfaq Mahmood ,  Matthias Friebe ,  Cristina Bolzati ,  Alun G. Jones ,  Alan Davison

    发明人： Ashfaq Mahmood ,  Matthias Friebe ,  Cristina Bolzati ,  Alun G. Jones ,  Alan Davison

    IPC分类号： A61K51/04 ,  C07F5/00 ,  C07D211/00 ,  A61P35/00 ,  C07D295/00

    CPC分类号： C07D295/13 ,  A61K51/0478 ,  C07C323/41 ,  C07F13/005 ,  C07K5/06026

    摘要： The present invention relates to compounds and related technetium and rhenium complexes thereof which are suitable for imaging or therapeutic treatment of tumors, e.g., carcinomas, melanomas and other tumors. In another embodiment, the invention relates to methods of imaging tumors using radiolabeled metal complexes. Preferred radiolabeled complexes for imaging tumors include technetium and rhenium complexes. The high tumor uptake and significant tumor/nontumor ratios of the technetium complexes of the invention indicate that such small technetium-99m-based molecular probes can be developed as in-vivo diagnostic agents for melanoma and its metastases. In yet another embodiment, the invention relates to methods of treatment of tumors using a radiolabeled metal complex as a radiopharmaceutical agent to treat the tumor.

    摘要翻译： 本发明涉及适用于肿瘤例如癌，黑素瘤和其他肿瘤的成像或治疗性治疗的化合物及其相关的锝和铼络合物。 在另一个实施方案中，本发明涉及使用放射性标记的金属络合物成像肿瘤的方法。 用于成像肿瘤的优选放射性标记复合物包括锝和铼络合物。 本发明的锝络合物的高肿瘤摄取和显着的肿瘤/非肿瘤比率表明，这种基于锝-99m的小分子探针可以作为黑色素瘤及其转移的体内诊断剂开发。 在另一个实施方案中，本发明涉及使用放射性标记的金属络合物作为放射性药物治疗肿瘤的方法治疗肿瘤。